Seminars in nuclear medicine最新文献_第2页

Demystifying the Role of Immuno PET-CT in Non-Small Cell Lung Cancer: Clinical Value and Research Trends

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.004

Sobhan Vinjamuri MD, Vineet Pant MD

引用次数: 0

Theranostics in Lung Neuroendocrine Tumors

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.010

Indraja D. Dev MD , Ameya D. Puranik DNB , Nikolaos A. Trikalinos MD , Bradley John Girod MD , Hyun Kim MD , Vikas Prasad MD

{"title":"Theranostics in Lung Neuroendocrine Tumors","authors":"Indraja D. Dev MD , Ameya D. Puranik DNB , Nikolaos A. Trikalinos MD , Bradley John Girod MD , Hyun Kim MD , Vikas Prasad MD","doi":"10.1053/j.semnuclmed.2025.02.010","DOIUrl":"10.1053/j.semnuclmed.2025.02.010","url":null,"abstract":"<div><div>In the last 2 decades, there has been a noticeable increase in the incidence of neuroendocrine tumors, in part due to improved understanding of pathology and/or availability of more sensitive and accurate diagnostic tests. While gastrointestinal tract and pancreas are the most common sites of origin, lung neuroendocrine tumors (LNETs) are also frequently reported and need special considerations from diagnostic as well as therapeutic aspects.</div><div>Radiopharmaceutical therapy (Theranostics) is a novel approach which utilizes a pair of diagnostic and therapeutic agents that share a common target on tumor sites. Precise treatment of the disease with minimum side effects is the principal aim of Theranostics.</div><div>It's a known fact that somatostatin receptors (SSTR) are abundantly expressed in neuroendocrine tumors. With the advent of highly specific radiopharmaceuticals targeting SSTR receptors for both diagnosis as well as treatment and other targeted therapies, management of LNETs has become less challenging. Still, there exists significant ambiguity in relation to management of LNETs with a scope of novel diagnostic and therapeutic strategies to pitch in.</div><div>This review focuses on the role of established evidence for Theranostics strategies in the management of LNETs and highlights the potential future role of newer targets which would be of promising value in addressing such rare and complex tumor biology.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 221-233"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.001

Manar Badarna MD , Zohar Keidar MD, PhD , Elite Arnon-Sheleg MD

引用次数: 0

FDG PET/CT for Staging Lung Carcinoma: An Update

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.01.002

Chabi Sathekge MD , Justine Maes MD , Alex Maes MD, PhD , Christophe Van de Wiele MD, PhD

{"title":"FDG PET/CT for Staging Lung Carcinoma: An Update","authors":"Chabi Sathekge MD , Justine Maes MD , Alex Maes MD, PhD , Christophe Van de Wiele MD, PhD","doi":"10.1053/j.semnuclmed.2025.01.002","DOIUrl":"10.1053/j.semnuclmed.2025.01.002","url":null,"abstract":"<div><div>In non-small cell lung carcinoma (NSCLC) carcinoma, the CT-part of the FDG PET/CT examination is of primary importance for T (tumor)-status assessment, while information derived from the primary tumor on the FDG-part of the examination may provide additional information on N- (lymph node) status. FDG PET/CT imaging was shown to have an overall sensitivity of 85% and a specificity of 84% for identifying LN involvement in NSCLC. Parameters that may predict the presence and quantify the risk of LN-involvement in NSCLC missed on FDG PET/CT imaging are tumor size and its increase over time, tumor differentiation degree, the number of days elapsed from the time of initial diagnosis, an adenocarcinoma subtype, a central versus peripheral location of the primary tumor and a solid versus mixed solid-ground glass radiologic character. Nomograms incorporating several of these variables have been published and made available for clinical usage. Furthermore, FDG PET/CT imaging was shown to have an overall higher sensitivity for identifying extra-thoracic metastases than convential morphological imaging and this especially for bone and adrenal lesions. In small cell lung carcinoma (SCLC), limited available data have shown FDG PET/CT imaging to be systematically more accurate for staging purposes when compared to conventional staging and to lead to a change in disease stage (limited versus extensive disease) in up to 15% of SCLC-patients.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 167-174"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FAPI PET in the Management of Lung Tumors

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.011

Anne-Leen Deleu MD , Qaid Ahmed Shagera MD, PhD , Sophie Veldhuijzen van Zanten MD, PhD , Patrick Flamen MD, PhD , Olivier Gheysens MD, PhD , Hubertus Hautzel MD, PhD

{"title":"FAPI PET in the Management of Lung Tumors","authors":"Anne-Leen Deleu MD , Qaid Ahmed Shagera MD, PhD , Sophie Veldhuijzen van Zanten MD, PhD , Patrick Flamen MD, PhD , Olivier Gheysens MD, PhD , Hubertus Hautzel MD, PhD","doi":"10.1053/j.semnuclmed.2025.02.011","DOIUrl":"10.1053/j.semnuclmed.2025.02.011","url":null,"abstract":"<div><div>Fibroblast activation protein (FAP), selectively expressed on activated fibroblasts in proliferating tissues, is emerging as a promising target in oncology. In lung cancer, the leading cause of cancer-related deaths worldwide, [<sup>18</sup>F]FDG PET/CT has set the bar high and earned widespread recognition in clinical guidelines for its essential role in staging and follow-up. Yet, FAP-targeted imaging agents like FAPI PET/CT have demonstrated significant potential due to their high tumor specificity, rapid tracer uptake, and low background activity. This review focuses on the role of FAPI PET/CT in lung cancer, highlighting its applications in staging, biomarker evaluation, and clinical management. FAP expression correlates with cancer associated fibroblast-driven tumorigenesis in lung cancer, showing higher expression in nonsmall cell lung cancer (NSCLC) than in small cell lung cancer (SCLC) subtypes. Studies reveal that FAPI PET/CT provides comparable or superior detection rates for primary tumors and metastases compared to [<sup>18</sup>F]FDG PET/CT, particularly in brain, pleural, and bone lesions. It also enhances accuracy in lymph node staging, influencing disease management by enabling surgical resection in cases misclassified by [<sup>18</sup>F]FDG PET/CT. Despite these advantages, several challenges remain, such as differentiating benign from malignant lesions, assessing FAPI's prognostic implications or its role in treatment response monitoring. Future directions include exploring FAPI-based theranostics, standardizing radiopharmaceuticals, and conducting well-designed, adequately powered prospective trials. FAPI PET/CT represents a transformative diagnostic tool, complementing or potentially surpassing [<sup>18</sup>F]FDG PET/CT in precision lung cancer care.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 202-211"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143557439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Role Does PET/MRI Play in Musculoskeletal Disorders? PET/MRI在肌肉骨骼疾病中的作用?

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2023.11.004

Tugce Telli MD , Mélanie Desaulniers MD, FRCPC , Thomas Pyka MD , Federico Caobelli MD, FEBNM , Sophia Forstmann MD , Lale Umutlu MD , Wolfgang P. Fendler MD , Axel Rominger MD , Ken Herrmann MD, MBA , Robert Seifert MD, MBA

{"title":"What Role Does PET/MRI Play in Musculoskeletal Disorders?","authors":"Tugce Telli MD , Mélanie Desaulniers MD, FRCPC , Thomas Pyka MD , Federico Caobelli MD, FEBNM , Sophia Forstmann MD , Lale Umutlu MD , Wolfgang P. Fendler MD , Axel Rominger MD , Ken Herrmann MD, MBA , Robert Seifert MD, MBA","doi":"10.1053/j.semnuclmed.2023.11.004","DOIUrl":"10.1053/j.semnuclmed.2023.11.004","url":null,"abstract":"<div><div><span>Musculoskeletal disorders<span> of nononcological origin are one of the most frequent reasons for consultation. Patients suffering from musculoskeletal disorders also consult more than once for the same reason. This results in multiple clinical follow-ups after several radiological and serum examinations, the main ones including X-rays targeting the painful anatomical region and inflammatory serum parameters. As part of their work up, patients suffering from musculoskeletal disorders often require multisequence, multi-parameter MRI. PET/MRI is a promising imaging modality for their diagnosis, with the added advantage of being able to be performed in a single visit. PET/MRI is particularly useful for diagnosing osteomyelitis, </span></span>spondylodiscitis<span>, arthritis, many pediatric pathologies<span>, and a wide range of other musculoskeletal pathologies. PET/MRI is already used to diagnose malignant bone tumors such as osteosarcoma. However, current knowledge of the indications for PET/MRI in nononcological musculoskeletal disorders is based on studies involving only a few patients. This review focuses on the usefulness of PET/MRI for diagnosing nononcological musculoskeletal disorders.</span></span></div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 277-289"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET/MRI in Non-Small Cell Lung Cancer (NSCLC)

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.009

Fawziah Alorfi MD , Jamshed Bomanji MD, PhD , Linda Bertoletti MD , Francesco Fraioli MD

{"title":"PET/MRI in Non-Small Cell Lung Cancer (NSCLC)","authors":"Fawziah Alorfi MD , Jamshed Bomanji MD, PhD , Linda Bertoletti MD , Francesco Fraioli MD","doi":"10.1053/j.semnuclmed.2025.02.009","DOIUrl":"10.1053/j.semnuclmed.2025.02.009","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer-related deaths worldwide, with nonsmall cell lung cancer (NSCLC) accounting for 80%-85% of cases. Accurate imaging is critical for staging, treatment planning, and follow-up. While CT and PET/CT are standard imaging modalities, PET/MR is a relatively new and promising radiation free technique combining the potentiality of MRI with the metabolic information of PET scans, allowing undeniable advantages including: superior contrast resolution, particularly in soft tissues; functional information through specific MRI sequences (eg, diffusion-weighted and perfusion sequences), reflecting changes at a cellular level; and more superior sensitivity compared to CT and PET/CT for detecting metastases in common metastatic sites such as the brain, liver, adrenal glands, and bone. These advantages position PET/MR as a valuable tool in comprehensive lung cancer staging. While it is not yet a routine clinical tool, ongoing advancements in imaging technology, protocol optimization, and large-scale studies may establish PET/MR as a key component in the personalized management of lung cancer.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 234-239"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.005

Busra Cangut MD, MS, Rahman Akinlusi MD, Ava Mohseny MD, Nasrin Ghesani MD, Munir Ghesani MD

{"title":"Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals","authors":"Busra Cangut MD, MS, Rahman Akinlusi MD, Ava Mohseny MD, Nasrin Ghesani MD, Munir Ghesani MD","doi":"10.1053/j.semnuclmed.2025.02.005","DOIUrl":"10.1053/j.semnuclmed.2025.02.005","url":null,"abstract":"<div><div>Lung cancer is one of the most common and deadliest forms of cancer worldwide. Over the past two decades, significant changes have occurred in the classification of lung cancer, involving multidisciplinary input and emphasizing the growing contribution of immunohistochemistry and molecular techniques to morphology in the classification scheme. This comprehensive review will cover the background and epidemiology of lung cancer as well as advancements in its staging and management, including discussions of new surgical techniques, targeted therapies, and immunotherapy. The review will detail the role of 18F-FDG-PET-CT in lung cancer, highlighting its importance in staging, treatment response assessment, and recurrence detection. While immunotherapy has transformed lung cancer management and improved patient outcomes, it presents major challenges and opportunities for optimal assessment of treatment response in lung cancer patients using 18F-FDG-PET-CT. This review will also explore future directions, including a discussion of promising new targeted diagnostic radiopharmaceuticals for PET/CT imaging. Additionally, there will be a brief discussion of evolving and exciting treatment options for lung cancer using targeted therapeutic radiopharmaceuticals. Several case-based illustrations are included to exemplify the role of 18F-FDG-PET-CT in various clinical scenarios.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 264-276"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of AI in the Evaluation of Neuroendocrine Tumors: Current State of the Art.

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-28 DOI: 10.1053/j.semnuclmed.2025.02.003

Felipe Lopez-Ramirez, Mohammad Yasrab, Florent Tixier, Satomi Kawamoto, Elliot K Fishman, Linda C Chu

引用次数: 0

AI in Breast Cancer Imaging: An Update and Future Trends.

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-25 DOI: 10.1053/j.semnuclmed.2025.01.008

Yizhou Chen, Xiaoliang Shao, Kuangyu Shi, Axel Rominger, Federico Caobelli

{"title":"AI in Breast Cancer Imaging: An Update and Future Trends.","authors":"Yizhou Chen, Xiaoliang Shao, Kuangyu Shi, Axel Rominger, Federico Caobelli","doi":"10.1053/j.semnuclmed.2025.01.008","DOIUrl":"https://doi.org/10.1053/j.semnuclmed.2025.01.008","url":null,"abstract":"<p><p>Breast cancer is one of the most common types of cancer affecting women worldwide. Artificial intelligence (AI) is transforming breast cancer imaging by enhancing diagnostic capabilities across multiple imaging modalities including mammography, digital breast tomosynthesis, ultrasound, magnetic resonance imaging, and nuclear medicines techniques. AI is being applied to diverse tasks such as breast lesion detection and classification, risk stratification, molecular subtyping, gene mutation status prediction, and treatment response assessment, with emerging research demonstrating performance levels comparable to or potentially exceeding those of radiologists. The large foundation models are showing remarkable potential in different breast cancer imaging tasks. Self-supervised learning gives an insight into data inherent correlation, and federated learning is an alternative way to maintain data privacy. While promising results have been obtained so far, data standardization from source, large-scale annotated multimodal datasets, and extensive prospective clinical trials are still needed to fully explore and validate deep learning's clinical utility and address the legal and ethical considerations, which will ultimately determine its widespread adoption in breast cancer care. We hereby provide a review of the most up-to-date knowledge on AI in breast cancer imaging.</p>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0